Mediolanum International Funds Ltd Buys 37,131 Shares of Zoetis Inc. $ZTS

Mediolanum International Funds Ltd boosted its stake in Zoetis Inc. (NYSE:ZTS) by 17.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 248,435 shares of the company’s stock after purchasing an additional 37,131 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Zoetis were worth $35,541,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ZTS. Halbert Hargrove Global Advisors LLC lifted its holdings in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the period. REAP Financial Group LLC raised its position in Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares in the last quarter. NewSquare Capital LLC lifted its stake in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the last quarter. Financial Consulate Inc. acquired a new stake in shares of Zoetis in the 3rd quarter valued at $39,000. Finally, SJS Investment Consulting Inc. increased its stake in shares of Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after purchasing an additional 257 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZTS has been the subject of several recent analyst reports. Barclays assumed coverage on Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a report on Wednesday, December 3rd. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research note on Thursday, December 18th. HSBC set a $140.00 price objective on shares of Zoetis in a research report on Wednesday, December 10th. Finally, The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $152.45.

Zoetis Stock Performance

Shares of ZTS stock opened at $124.79 on Friday. The firm has a market capitalization of $54.99 billion, a price-to-earnings ratio of 21.01, a PEG ratio of 2.10 and a beta of 0.97. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The business’s 50-day moving average price is $124.08 and its 200-day moving average price is $137.15. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.40.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same quarter last year, the business earned $1.58 EPS. The firm’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a $0.53 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s payout ratio is presently 35.69%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.